INTRODUCTION
============

Liver biopsy has traditionally been used for determining the index fibrosis in patients with chronic liver disease. However, its usefulness is limited by invasiveness, cost, sampling error, and the difficulty of monitoring the progression of fibrosis over time \[[@b1-ce-2017-095]-[@b3-ce-2017-095]\].

Over the past several years, there has been significant interest in assessing the utility of non-invasive techniques for the evaluation of liver disease \[[@b3-ce-2017-095],[@b4-ce-2017-095]\]. The most promising and prevailing technique thus far is tissue elastography, a method that can effectively determine liver stiffness or compressibility and has been validated for the staging of liver fibrosis \[[@b5-ce-2017-095],[@b6-ce-2017-095]\]. One form of elastography, called transient elastography (FibroScan™), is a now widely used transabdominal probe-based device; however, it is less sensitive in patients with ascites, thick subcutaneous fat, narrow intercostal spaces, and hepatic atrophy \[[@b7-ce-2017-095]-[@b10-ce-2017-095]\]. Furthermore, significant intra- and inter-observer variability has been found based on the degree of probe compression during data collection, along with decreased accuracy in diagnosing moderate fibrosis \[[@b2-ce-2017-095],[@b4-ce-2017-095],[@b7-ce-2017-095],[@b9-ce-2017-095],[@b11-ce-2017-095],[@b12-ce-2017-095]\].

Real-time elastography (RTE) is another type of elastography that may be more sensitive than transient elastography in diagnosing the degree of liver fibrosis. This novel technology uses image enhancement to display differences in tissue compressibility. Liver fibrosis index (LFI) can be determined using this method, with validation studies demonstrating that an LFI greater than 2.56 correlates with METAVIR scores of F4 \[[@b13-ce-2017-095]\]. Additionally, RTE does not require ultrasound probe compression for image acquisition, thereby decreasing the variability associated with transient elastography \[[@b13-ce-2017-095]-[@b15-ce-2017-095]\].

While studies to date have focuses on transabdominal RTE, endoscopic ultrasound (EUS) RTE may provide a simplified treatment option for patients with liver disease, many of whom are already undergoing endoscopic examination for variceal screening and surveillance. Moreover, EUS RTE may be theoretically more sensitive than transabdominal RTE in the detection of the degree of liver fibrosis because the EUS approach requires signal penetration through a thin gastric wall (usually at most 5 mm) compared to the transabdominal approach, which requires signal penetration through the thick abdominal wall (usually several centimeters) ([Fig. 1](#f1-ce-2017-095){ref-type="fig"}). In this pilot study, we sought to assess whether LFI obtained via EUS RTE could distinguish normal, fatty, and cirrhotic liver tissue in a cohort of patients with chronic liver disease.

Materials and methods
=====================

Study design
------------

This was a prospective cohort study. The basic design is shown in [Fig. 1](#f1-ce-2017-095){ref-type="fig"}. Consecutive patients requiring EUS were prospectively enrolled. The endoscopist was blinded to the patients' history of liver disease. The study was approved by the Partners Healthcare Institutional Review Board prior to inception. Fifty consecutive patients who had undergone abdominal imaging performed within six months of EUS RTE that indicated normal, fatty, or cirrhotic liver tissue were then enrolled. One experienced operator performed all RTE examinations. At the time of the endoscopy, the proceduralist was blinded to the severity and etiology of chronic liver disease, and the LFI was calculated following completion of the procedure. All procedures were performed under propofol anesthesia. Demographic information detailed in the medical record was available for all patients.

Study population and assembly of patients
-----------------------------------------

Patients were recruited from the Gastroenterology and Hepatology clinics at Brigham and Women's Hospital. All patients were referred by an experienced, board-certified gastroenterologist and/or hepatologist and had a clinical indication to undergo EUS. These patients were contacted by phone by a member of the study staff if additional questions arose, and the procedure was discussed in detail at that time. If the patient agreed to undergo the procedure, he/she formally consented at the time of the endoscopy. Inclusion and exclusion criteria are shown in [Fig. 2](#f2-ce-2017-095){ref-type="fig"}.

Data acquisition
----------------

The RTE machine utilized for this study was the Preirus™ EUS system (Pentax, Montvale, NJ, USA). This modality displays elastic information and the strain of the tissue, which is calculated from the tissue displacement produced by internal compression and relaxation of the heart.

During EUS, proprietary analysis software (Hitachi Medical Systems Europe) was used to calculate six RTE images of the left liver via a transgastric approach. These images were collected for each patient and analyzed with proprietary software to evaluate nine image features (mean of the relative strain value, standard deviation of the relative strain value, ratio of blue area in the analyzed region, complexity of the blue area, kurtosis of the strain histogram, skewness of the strain histogram, entropy, inverse difference moment, and angular second moment) and to synthesize a single value known as the LFI.

Outcomes
--------

We sought to determine whether LFI obtained via EUS RTE could distinguish normal, fatty, and cirrhotic liver tissue in accordance with previously obtained abdominal imaging.

Statistical analysis
--------------------

A univariate analysis was performed to compare baseline characteristics between patients with normal, fatty, and cirrhotic liver imaging. Chi-square analyses were performed for all binary and categorical variables, and *t*-tests were performed for continuous variables. Pairwise comparisons between groups were performed using *t*-tests and ANOVA, and reported as mean±standard error (SE), with a two-sided *p*-value of \<0.05 considered significant. Multivariable regression analysis was performed to determine whether LFI was associated with cirrhosis as determined based on abdominal imaging findings. All statistical analyses were performed using the SAS 9.4 statistical package (SAS Institute Inc., Cary, NC, USA).

RESULTS
=======

A total of 50 consecutive patients with clinical indications to undergo EUS were enrolled ([Fig. 2](#f2-ce-2017-095){ref-type="fig"}). All patients had abdominal imaging prior to endoscopic evaluation, and prior biopsy results indicated normal liver, fatty liver, and cirrhosis in 26, 16, and 8 patients, respectively. Baseline characteristics for each study group and the etiologies of cirrhosis are shown in [Table 1](#t1-ce-2017-095){ref-type="table"}.

All patients successfully completed the procedure. There were no intra- or peri-procedural adverse events. Mean procedure time was 34 minutes (+/-- 5.4 SE). The RTE component accounted for a mean 5 minutes (+/-- 1.7 SE) of the total procedure time. Representative images from each of the three groups are shown in [Fig. 3](#f3-ce-2017-095){ref-type="fig"}. The cirrhotic group showed significantly increased mean LFI scores compared to the fatty liver (3.2 vs. 1.7, *p*\<0.001) and normal (3.2 vs. 0.8, *p*\<0.001) groups ([Fig. 4](#f4-ce-2017-095){ref-type="fig"}). The fatty liver group had significantly increased LFI scores compared to the normal group (3.8 vs. 1.4, *p*\<0.001) ([Fig. 4](#f4-ce-2017-095){ref-type="fig"}).

Multivariable regression suggested that LFI was an independent predictor of group features (*p*\<0.001) when adjusting for other variables including age and sex. Using the previously published LFI cut-off of 2.56, the area under the receiver operator characteristic (ROC) curve for LFI in predicting cirrhosis on imaging was 0.865, which suggests strong predictive value ([Fig. 5](#f5-ce-2017-095){ref-type="fig"}).

DISCUSSION
==========

Cirrhosis represents a late stage of progressive hepatic fibrosis, in which healthy tissue is replaced by scar tissue, leading to hepatic dysfunction. Liver biopsy has traditionally been used for determining the index of liver fibrosis using a METAVIR score ranging from F0 (no fibrosis) to F4 (cirrhosis). However, the usefulness of liver biopsy is limited by invasiveness, cost, potential complications, and difficulty of repeated procedures for the monitoring of changes over time. Furthermore, a standard liver biopsy sample lacks accuracy due to sampling error \[[@b3-ce-2017-095]\], and its histologic interpretation is prone to substantial subjectivity, leading to discordance in staging in up to 40% of patients \[[@b1-ce-2017-095]-[@b4-ce-2017-095]\].

RTE is a novel technology that offers an alternative method of image enhancement to display the differences in compressibility between tissues. As the name implies, the images are obtained in real time, allowing for the visualization of a two-dimensional strain image induced by internal heartbeats. The pattern of the induced strain image becomes patchy as fibrosis progresses. Previous work using transabdominal RTE has confirmed that LFI computed from RTE images highly correlates with the METAVIR stages of hepatic fibrosis, with significant differences existing between all stages. This relationship remains valid even in the presence of inflammation.

In this clinical pilot study, we assessed whether LFI obtained via EUS RTE could distinguish normal, fatty, and cirrhotic liver tissue in a cohort of patients undergoing EUS. We found that LFI computed from RTE images significantly correlated with abdominal imaging, and the ANOVA confirmed statistically significant differences between the normal, fatty, and cirrhotic-appearing livers. Furthermore, our multivariable regression analysis suggested that LFI was an independent predictor of group features when adjusting for other variables. Using the previously published LFI cut-off of 2.56, the area under the ROC curve for predicting cirrhosis on imaging with LFI demonstrated a very strong predictive value.

RTE has several advantages over transient elastography. First, since it does not have the same limitations as transient elastography, it can be used in all patients. It has also been demonstrated to be more sensitive than transient elastography in diagnosing the degree of liver fibrosis, with LFI \>2.56 correlating with METAVIR scores of F4 \[[@b14-ce-2017-095]\]. Additionally, RTE does not require ultrasound probe compression for image acquisition, which attenuates the variability associated with transient elastography. Additionally, unlike transient elastography, which can only be performed transabdominally, RTE can be performed transabdominally or endoscopically (i.e., via an echo ultrasound probe) and can therefore be employed at the time of screening and surveying for esophageal varices in patients with chronic liver disease. Finally, EUS RTE may be potentially advantageous in patients for whom transabdominal imaging would be inaccurate, i.e., those with ascites or thick subcutaneous fat.

There are several limitations to our study. First, the small number of patients with cirrhosis may limit the power to detect differences and to achieve more extensive controlling of variables with statistical significance. Second, we did not have biopsy data on all patients; therefore, the patients' livers were labeled a priori as normal, fatty, and cirrhotic based on imaging studies. Third, all of our procedures were performed by a single proceduralist with expertise in therapeutic endoscopy. While this helped to standardize the results obtained from the RTE, it is unclear if this association would be as significant or consistent in users with less experience in therapeutic endoscopy.

The results of the present study are encouraging in that they demonstrate the ability of RTE to discriminate normal, fatty, and cirrhotic liver tissue based on cross-sectional imaging, with LFI showing significant predictive value for cirrhosis. Given these results, further studies are underway to determine the comparison with transabdominal RTE and concomitant liver biopsy, as well as the prediction scores for decompensation.
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![Schematic demonstration of endoscopic ultrasound-based real time elastography, which can evaluate both the right and left liver through the gastrointestinal wall compared to trans-abdominal elastography, which requires signal transmission through the thick abdominal wall.](ce-2017-095f1){#f1-ce-2017-095}

![Flowchart showing the basic study design. EGD, esophagogastroduodenoscopy; EUS, endoscopic ultrasound; LFI, liver fibrosis index; INR, international normalized ratio.](ce-2017-095f2){#f2-ce-2017-095}

![Representative endoscopic ultrasound real-time elastography images in patients with normal (A), fatty (B), and cirrhotic (C) liver tissue on cross-sectional imaging.](ce-2017-095f3){#f3-ce-2017-095}

![Comparison of liver fibrosis index (LFI) scores between the normal, fatty, and cirrhotic liver imaging (ANOVA).](ce-2017-095f4){#f4-ce-2017-095}

![Area under the receiver operator characteristic (ROC) curve for the prediction of cirrhosis on imaging by liver fibrosis index (LFI).](ce-2017-095f5){#f5-ce-2017-095}

###### 

Baseline Characteristics of Patients Included in the Study

  Variable                Normal (*n*=26)   Fatty (*n*=16)   Cirrhosis^[a)](#tfn1-ce-2017-095){ref-type="table-fn"}^ (*n*=8)
  ----------------------- ----------------- ---------------- -----------------------------------------------------------------
  Age (mean±SD)           59.3±18           58.3±17          64.2±14
  Sex, male               12 (43)           7 (44)           4 (50)
  BMI kg/m^2^ (mean±SD)   29.0±6            30.8±7           28.3±4
  Hypertension            10 (37)           12 (71)          7 (88)
  Hyperlipidemia          4 (15)            9 (53)           4 (50)
  Diabetes                1 (4)             4 (24)           6 (75)
  Tobacco use             4 (15)            3 (18)           4 (50)
  Alcohol use             9 (33)            5 (29)           5 (63)

SD, standard deviation; BMI, body mass index.

Etiology of cirrhosis: alcoholic (*n*=2); alcoholic+hepatitis C (*n*=2); alcoholic+hepatitis B (*n*=1); hepatitis B (*n*=1); non-alcoholic steatohepatitis (*n*=2).
